Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome

NCT00857818 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

64

Enrollment

INDUSTRY

Sponsor class

Stopped Slow Accrual

Conditions

Schizophrenia
Schizoaffective Disorder
Bipolar I Disorder
Metabolic Syndrome

Interventions

DRUG: Aripiprazole
DRUG: Oanzapine, risperidone, or quetiapine

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.